1-Piperidinepropanenitrile, 3-[(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)methylamino]-4-methyl-β-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) manufacturers
|
| | 1-Piperidinepropanenitrile, 3-[(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)methylamino]-4-methyl-β-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) Basic information |
| Product Name: | 1-Piperidinepropanenitrile, 3-[(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)methylamino]-4-methyl-β-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) | | Synonyms: | 1-Piperidinepropanenitrile, 3-[(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)methylamino]-4-methyl-β-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1);Tofacitinib Impurity N (Citrate);Tofacitinib Related Compound 21 Citrate;1-Piperidinepropanenitrile, 3-[(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)methylamino]-4-methyl-β-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) | | CAS: | 1809002-40-1 | | MF: | C22H30N6O8 | | MW: | 506.52 | | EINECS: | | | Product Categories: | | | Mol File: | 1809002-40-1.mol | ![1-Piperidinepropanenitrile, 3-[(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)methylamino]-4-methyl-β-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) Structure](CAS/20211123/GIF/1809002-40-1.gif) |
| | 1-Piperidinepropanenitrile, 3-[(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)methylamino]-4-methyl-β-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) Chemical Properties |
| | 1-Piperidinepropanenitrile, 3-[(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)methylamino]-4-methyl-β-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) Usage And Synthesis |
| | 1-Piperidinepropanenitrile, 3-[(6,7-dihydro-5H-pyrrolo[2,3-d]pyrimidin-4-yl)methylamino]-4-methyl-β-oxo-, (3R,4R)-, 2-hydroxy-1,2,3-propanetricarboxylate (1:1) Preparation Products And Raw materials |
|